Department of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
United European Gastroenterol J. 2023 Sep;11(7):601-611. doi: 10.1002/ueg2.12422. Epub 2023 Jul 12.
Surveillance of pancreatic cysts focuses on the detection of (mostly morphologic) features warranting surgery. European guidelines consider elevated CA19.9 as a relative indication for surgery. We aimed to evaluate the role of CA19.9 monitoring for early detection and management in a cyst surveillance population.
The PACYFIC-registry is a prospective collaboration that investigates the yield of pancreatic cyst surveillance performed at the discretion of the treating physician. We included participants for whom at least one serum CA19.9 value was determined by a minimum follow-up of 12 months.
Of 1865 PACYFIC participants, 685 met the inclusion criteria for this study (mean age 67 years, SD 10; 61% female). During a median follow-up of 25 months (IQR 24, 1966 visits), 29 participants developed high-grade dysplasia (HGD) or pancreatic cancer. At baseline, CA19.9 ranged from 1 to 591 kU/L (median 10 kU/L [IQR 14]), and was elevated (≥37 kU/L) in 64 participants (9%). During 191 of 1966 visits (10%), an elevated CA19.9 was detected, and these visits more often led to an intensified follow-up (42%) than those without an elevated CA19.9 (27%; p < 0.001). An elevated CA19.9 was the sole reason for surgery in five participants with benign disease (10%). The baseline CA19.9 value was (as continuous or dichotomous variable at the 37 kU/L threshold) not independently associated with HGD or pancreatic cancer development, whilst a CA19.9 of ≥ 133 kU/L was (HR 3.8, 95% CI 1.1-13, p = 0.03).
In this pancreatic cyst surveillance cohort, CA19.9 monitoring caused substantial harm by shortening surveillance intervals (and performance of unnecessary surgery). The current CA19.9 cutoff was not predictive of HGD and pancreatic cancer, whereas a higher cutoff may decrease false-positive values. The role of CA19.9 monitoring should be critically appraised prior to implementation in surveillance programs and guidelines.
胰腺囊肿的监测重点在于发现(主要是形态学)需要手术的特征。欧洲指南认为 CA19.9 升高是手术的相对指征。我们旨在评估 CA19.9 监测在囊肿监测人群中的早期发现和管理中的作用。
PACYFIC 登记处是一项前瞻性合作研究,调查了由主治医生自行决定进行的胰腺囊肿监测的效果。我们纳入了至少随访 12 个月且至少有一次血清 CA19.9 值的参与者。
在 1865 名 PACYFIC 参与者中,有 685 名符合本研究的纳入标准(平均年龄 67 岁,标准差 10 岁;61%为女性)。在中位随访 25 个月(IQR 24,1966 次就诊)期间,有 29 名参与者发展为高级别异型增生(HGD)或胰腺癌。基线时,CA19.9 范围为 1 至 591kU/L(中位数 10kU/L[IQR 14]),64 名参与者(9%)的 CA19.9 升高(≥37kU/L)。在 1966 次就诊中的 191 次(10%)中检测到 CA19.9 升高,与未升高的 CA19.9 就诊相比,这些就诊更常导致强化随访(42%比 27%;p<0.001)。在 5 名患有良性疾病的患者中,CA19.9 升高是手术的唯一原因(10%)。CA19.9 基线值(作为连续或离散变量在 37kU/L 阈值)与 HGD 或胰腺癌的发展不独立相关,而 CA19.9≥133kU/L 与 HGD 或胰腺癌的发展相关(HR 3.8,95%CI 1.1-13,p=0.03)。
在这个胰腺囊肿监测队列中,CA19.9 监测通过缩短监测间隔(并进行不必要的手术)造成了实质性的危害。目前的 CA19.9 截断值不能预测 HGD 和胰腺癌,而较高的截断值可能会减少假阳性值。在将 CA19.9 监测纳入监测计划和指南之前,应严格评估其作用。